HK Stock Market Move | INSILICO(03696) rises over 6% intraday; the company's first AI drug demonstrates anti-aging potential; institutions are bullish on an explosive commercialization of AI drug discovery.

INSILICO(03696) rose as much as over 6% intraday, up 4.87% as of press time at HK$52.75, with a turnover of HK$285 million. On the news front, an experimental drug Rentosertib developed by INSILICO for the treatment of lung disease previously showed positive prospects in reversing biomarkers of biological aging. Studies showed that patients' biological age could be reduced by up to 6 years as assessed by proteomic aging clocks. The drug has now entered Phase III clinical trials. Citi believes that INSILICO remains the bank's top pick in the artificial intelligence drug discovery (AIDD) sub-sector. It is worth noting that the AI pharmaceutical sector has recently seen a dense cluster of catalysts. GENSCRIPT BIO announced a collaboration with Lilly TuneLab, Eli Lilly's AI drug discovery platform, while Novo Nordisk also announced a partnership with Anthropic to accelerate new drug discovery. CMSC pointed out that from algorithmic narratives to pipeline value, clinical validation and commercialization explosion in AI pharmaceuticals are imminent.